SCHEMBL4060992

SCHEMBL4060992

Cc1cc(C)c2cccc(OCc3c(Cl)ccc(S(=O)(=O)NC(C)(C)C(=O)N4CCN(C(=O)[C@@H](N)CCCCNC(=N)N)CC4)c3Cl)c2n1

nearest known ligand 0.82

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
BDKRB2 P30411 20/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4060983 1.00 BDKRB2 (0.82) BDKRB2
SCHEMBL4063124 0.98 BDKRB2 (0.81) BDKRB2
SCHEMBL4063119 0.98 BDKRB2 (0.81) BDKRB2
SCHEMBL4065097 0.90 BDKRB2 (1.00) BDKRB2
SCHEMBL4065102 0.90 BDKRB2 (1.00) BDKRB2
SCHEMBL4058976 0.89 BDKRB2 (0.81) BDKRB2
SCHEMBL4069473 0.89 BDKRB2 (1.00) BDKRB2
SCHEMBL4058969 0.89 BDKRB2 (0.81) BDKRB2
SCHEMBL4069480 0.89 BDKRB2 (1.00) BDKRB2
SCHEMBL4060998 0.88 BDKRB2 (0.63) BDKRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513531-B1 BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM MENARINI RICERCHE SPA (IT) 2009-10-21 EP claimed
US-7491825-B2 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom MENARINI RICERCHE S.P.A. (IT) 2009-02-17 US claimed
US-20060205712-A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom MENARINI RIEERCHE S.P.A. (IT) 2006-09-14 US claimed
EP-1513531-A1 BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM Menarini Ricerche S.p.A. (IT) 2005-03-16 EP claimed
WO-2003103671-A1 BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM MENARINI RICERCHE S.P.A. (IT) 2003-12-18 WO claimed
EP-1513531-B1 BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM MENARINI RICERCHE SPA (IT) 2009-10-21 EP disclosed
US-7491825-B2 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom MENARINI RICERCHE S.P.A. (IT) 2009-02-17 US disclosed
US-20060205712-A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom MENARINI RIEERCHE S.P.A. (IT) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205712-A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom BDKRB2, BDKRB1, AGTR2 BDKRB2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.